Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Manuela Rizzo

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
Cell Death & Disease|September 25, 2021
New insight into the catalytic -dependent and -independent roles of METTL3 in sustaining aberrant translation in chronic myeloid leukemiaZaira Ianniello, Melissa Sorci, Lavinia Ceci Ginistrelli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 9, 2008
Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemiaLuca Maurillo, Francesco Buccisano, Maria Ilaria Del Principe, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2003
Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin's lymphoma: an Italian multicenter randomized trialMaurizio Martelli, Filippo Gherlinzoni, Amalia De Renzo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 14, 2010
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trialAntonio Palumbo, Sara Bringhen, Davide Rossi, et al.
Current Medical Research and Opinion|January 18, 2021
Adherence, persistence and efficacy of dasatinib and nilotinib in the treatment of patients resistant or intolerant to imatinib with chronic myeloid leukemia in chronic phase: an Italian multicenter study over two years in real lifeFiorenzo Santoleri, Elena Ranucci, Gaetano La Barba, et al.
Blood|December 8, 2009
Melphalan 200 mg/m(2) versus melphalan 100 mg/m(2) in newly diagnosed myeloma patients: a prospective, multicenter phase 3 studyAntonio Palumbo, Sara Bringhen, Benedetto Bruno, et al.
Journal of Hematology & Oncology|January 11, 2019
Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trialIlaria Saltarella, Fortunato Morabito, Nicola Giuliani, et al.
Neoplasia (New York, N.Y.)|September 24, 2016
Frontline Dasatinib Treatment in a "Real-Life" Cohort of Patients Older than 65 Years with Chronic Myeloid LeukemiaRoberto Latagliata, Fabio Stagno, Mario Annunziata, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Cell Death & Disease|September 25, 2021
New insight into the catalytic -dependent and -independent roles of METTL3 in sustaining aberrant translation in chronic myeloid leukemiaZaira Ianniello, Melissa Sorci, Lavinia Ceci Ginistrelli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 9, 2008
Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemiaLuca Maurillo, Francesco Buccisano, Maria Ilaria Del Principe, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2003
Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin's lymphoma: an Italian multicenter randomized trialMaurizio Martelli, Filippo Gherlinzoni, Amalia De Renzo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 14, 2010
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trialAntonio Palumbo, Sara Bringhen, Davide Rossi, et al.
Current Medical Research and Opinion|January 18, 2021
Adherence, persistence and efficacy of dasatinib and nilotinib in the treatment of patients resistant or intolerant to imatinib with chronic myeloid leukemia in chronic phase: an Italian multicenter study over two years in real lifeFiorenzo Santoleri, Elena Ranucci, Gaetano La Barba, et al.
Blood|December 8, 2009
Melphalan 200 mg/m(2) versus melphalan 100 mg/m(2) in newly diagnosed myeloma patients: a prospective, multicenter phase 3 studyAntonio Palumbo, Sara Bringhen, Benedetto Bruno, et al.
Journal of Hematology & Oncology|January 11, 2019
Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trialIlaria Saltarella, Fortunato Morabito, Nicola Giuliani, et al.
Neoplasia (New York, N.Y.)|September 24, 2016
Frontline Dasatinib Treatment in a "Real-Life" Cohort of Patients Older than 65 Years with Chronic Myeloid LeukemiaRoberto Latagliata, Fabio Stagno, Mario Annunziata, et al.
Pageof 3